2013 News Releases

Keyword Search
2018 | 2017 | 2016 | 2015 | 2014 | 2013
Date Title
Dec 09, 2013Printer Friendly VersionUpdated Data with Oral Proteasome Inhibitor MLN9708 Reported in Newly Diagnosed Multiple Myeloma Patients
Dec 09, 2013Printer Friendly VersionSeattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
Dec 07, 2013Printer Friendly VersionAnalysis Suggests Increased Overall Survival with Use of Higher Cumulative Dose of VELCADE® (bortezomib) in Patients with Previously Untreated Multiple Myeloma
Nov 11, 2013Printer Friendly VersionTakeda Announces 118 Abstracts on VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Leading Pipeline Compounds to be Presented at 55th American Society of Hematology Annual Meeting
Jul 25, 2013Printer Friendly VersionTakeda Announces Unblinding of Phase 3 Study of Orteronel in Patients with Metastatic, Castration-Resistant Prostate Cancer That Progressed Post-Chemotherapy Based on Interim Analysis
Jun 19, 2013Printer Friendly VersionTakeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma
Jun 03, 2013Printer Friendly VersionASCO Presentation Highlights Results of Single Agent Oral MLN9708 in Heavily Pretreated Patients with Relapsed and/or Refractory Multiple Myeloma
Jun 01, 2013Printer Friendly VersionTakeda Highlights Data from Clinical Trial Examining the Use of ADCETRIS® (Brentuximab Vedotin) in Pediatric Patients
May 23, 2013Printer Friendly VersionTakeda Announces Organizational Changes at Millennium: The Takeda Oncology Company
May 23, 2013Printer Friendly VersionTakeda Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients with Newly Diagnosed Multiple Myeloma
Apr 07, 2013Printer Friendly VersionMeta-Analysis of VELCADE® (bortezomib)-Based Induction Therapy Followed by Stem-Cell Transplantation Showed Significantly Greater Response and Longer Progression-Free and Overall Survival in Patients with Multiple Myeloma
Apr 05, 2013Printer Friendly VersionTakeda and Millennium Announce Approval of ADCETRIS® (Brentuximab Vedotin) in Switzerland
Mar 29, 2013Printer Friendly VersionMillennium: The Takeda Oncology Company and the WIN Consortium Become Partners in the Fight Against Cancer
Jan 24, 2013Printer Friendly VersionSeattle Genetics and Millennium Initiate Global Phase III Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL)
Jan 23, 2013Printer Friendly VersionMultiple Myeloma Research Foundation (MMRF) Names Millennium Collaborator of the Year
Jan 16, 2013Printer Friendly VersionFortune Magazine Names Millennium Among 100 Best Companies To Work For